Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

SONN Sonnet BioTherapeutic

1.550
-0.090-5.49%
Close 10/06 16:00 ET
1.470
-0.080-5.16%
Post Mkt Price 10/06 18:49 ET
High
1.640
Open
1.640
Turnover
92.89K
Low
1.520
Pre Close
1.640
Volume
58.92K
Market Cap
7.71M
P/E(TTM)
Loss
52wk High
9.618
Shares
4.97M
P/E(Static)
Loss
52wk Low
1.230
Float Cap
7.51M
Bid/Ask %
60.00%
Historical High
1872.780
Shs Float
4.84M
Volume Ratio
0.45
Historical Low
1.230
Dividend TTM
--
Div Yield TTM
--
P/B
10.06
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.22%
Amplitude
7.32%
Avg Price
1.576
Lot Size
1
Float Cap
7.51M
Bid/Ask %
60.00%
Historical High
1872.780
Shs Float
4.84M
Volume Ratio
0.45
Historical Low
1.230
Dividend TTM
--
P/B
10.06
Dividend LFY
--
Turnover Ratio
1.22%
Amplitude
7.32%
Avg Price
1.576
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded in 2011 and is headquartered in Princeton, NJ.
CEO: Dr. Pankaj Mohan, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...